

This is a free sample of content from Intellectual Property in Molecular Medicine.
[Click here](#) for more information on how to buy the book.

Intellectual Property in Molecular Medicine

A subject collection from *Cold Spring Harbor Perspectives in Medicine*

**OTHER SUBJECT COLLECTIONS FROM COLD SPRING HARBOR
PERSPECTIVES IN MEDICINE**

Retinal Disorders: Genetic Approaches to Diagnosis and Treatment

The Biology of Heart Disease

Tuberculosis

The Skin and Its Diseases

MYC and the Pathway to Cancer

Bacterial Pathogenesis

Transplantation

Cystic Fibrosis: A Trilogy of Biochemistry, Physiology, and Therapy

Hemoglobin and Its Diseases

Addiction

Parkinson's Disease

Type 1 Diabetes

Angiogenesis: Biology and Pathology

HIV: From Biology to Prevention and Treatment

The Biology of Alzheimer Disease

**SUBJECT COLLECTIONS FROM COLD SPRING HARBOR
PERSPECTIVES IN BIOLOGY**

Mitosis

Glia

Human Fungal Pathogens

Innate Immunity and Inflammation

The Genetics and Biology of Sexual Conflict

The Origin and Evolution of Eukaryotes

Endocytosis

Mitochondria

Signaling by Receptor Tyrosine Kinases

DNA Repair, Mutagenesis, and Other Responses to DNA Damage

Cell Survival and Cell Death

Immune Tolerance

DNA Replication

Endoplasmic Reticulum

Wnt Signaling

Protein Synthesis and Translational Control

The Synapse

Extracellular Matrix Biology

Protein Homeostasis

Calcium Signaling

The Golgi

Germ Cells

Intellectual Property in Molecular Medicine

A subject collection from *Cold Spring Harbor Perspectives in Medicine*

EDITED BY

Salim Mamajiwalla

In(sci)te IP, Inc.

Rochelle Seide

R. Seide Consulting, LLC



COLD SPRING HARBOR LABORATORY PRESS
Cold Spring Harbor, New York • www.cshlpress.org

Intellectual Property in Molecular Medicine

A Subject Collection from *Cold Spring Harbor Perspectives in Medicine*

Articles online at www.perspectivesinmedicine.org

All rights reserved

© 2015 by Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
Printed in the United States of America

Executive Editor	Richard Sever
Managing Editor	Maria Smit
Senior Project Manager	Barbara Acosta
Permissions Administrator	Carol Brown
Production Editors	Diane Schubach, Kathleen Bubbeo
Production Manager/Cover Designer	Denise Weiss
Publisher	John Inglis

Front cover artwork: The figure on the *left* is a cartoon representation of the complex structure of the BRCA1 RING domain and the BARD1 RING domain (based on PyMOL rendering of PDB 1jm7). The figure on the *right* is a cartoon representation of the molecular structure of the protein registered with the PDB code 1n0w (BRCA2). Both were the subjects of patent applications filed by Myriad Genetics and other institutions in the 1990s because mutations in the genes encoding BRCA1 and BRCA2 are linked to breast and ovarian cancer. Subsequently, lawsuits were filed against Myriad Genetics by several entities alleging that patents for human genes are invalid. (The image on the *right* can be found in Wikipedia under "PBB Protein BRCA2 image." It is reprinted here courtesy of Public Domain via Wikimedia Commons. The image on the *left* has been released into the public domain by its creator and original copyright holder, Jawahar Swaminathan and the MSD staff at the European Bioinformatics Institute. The image is currently licensed under Public Domain via Wikimedia Commons. This applies worldwide. As such it is entirely free to reproduce, create derivative works, or make commercial use of as one sees fit, without any requirement to give the creator credit. However, as a courtesy, a link back to <http://www.ebi.ac.uk/> would be appreciated.)

Library of Congress Cataloging-in-Publication Data

Intellectual property in molecular medicine/edited by Salim Mamajiwalla, Rochelle Seide.
pages cm

Summary: "As universities increasingly spin off biotech companies and academics work more closely with these companies and the pharma industry, it is essential that they gain an understanding of intellectual property law and patenting. This book introduces the basic ideas and discusses how they apply to biomedical research and product development in the age of genomics"-- Provided by publisher.

Includes bibliographical references and index.

ISBN 978-1-62182-083-3 (hardback)

1. Biotechnology--Patents. 2. Intellectual property. 3. Molecular biology. I. Mamajiwalla, Salim, editor. II. Seide, Rochelle K., editor.

K1519.B54I56 2015

346.04'86--dc23

2014043946

10 9 8 7 6 5 4 3 2 1

All World Wide Web addresses are accurate to the best of our knowledge at the time of printing.

Authorization to photocopy items for internal or personal use, or the internal or personal use of specific clients, is granted by Cold Spring Harbor Laboratory Press, provided that the appropriate fee is paid directly to the Copyright Clearance Center (CCC). Write or call CCC at 222 Rosewood Drive, Danvers, MA 01923 (978-750-8400) for information about fees and regulations. Prior to photocopying items for educational classroom use, contact CCC at the above address. Additional information on CCC can be obtained at CCC Online at www.copyright.com.

For a complete catalog of all Cold Spring Harbor Laboratory Press publications, visit our website at www.cshlpress.org.

Contents

Preface, vii

Introduction to Intellectual Property: A U.S. Perspective, 1
Amanda Murphy, Michael Stramiello, Stacy Lewis, and Tom Irving

Impact of America Invents Act on Biotech Intellectual Property, 15
Amanda Murphy, Michael Stramiello, Jonathan Stroud, Stacy Lewis, and Tom Irving

Patenting the Life Sciences at the European Patent Office, 37
Christina Gates

The Role of Regulatory Agencies and Intellectual Property: Part I, 47
Kevin E. Noonan

The Role of Regulatory Agencies and Intellectual Property: Part II, 59
Kevin E. Noonan

Canada's Patented Medicines (Notice of Compliance) Proceedings and Intellectual Property, 75
Henry Bian and Conor McCourt

Inventorship and Authorship, 79
Antoinette F. Konski and Linda X. Wu

Must an Inventor "Possess" an Invention to Patent It?, 93
Warren D. Woessner and Robin A. Chadwick

What is Your Reasonable Expectation of Success in Obtaining Pharmaceutical or Biotechnology Patents Having Nonobvious Claimed Inventions That the Courts Will Uphold? An Overview of Obviousness Court Decisions, 103
Daniel J. Pereira and Stephen G. Kunin

Inherent Anticipation in the Pharmaceutical and Biotechnology Industries, 115
Michael Goldman, Georgia Evans, and Andrew Zappia

Baseball Bats and Chocolate Chip Cookies: The Judicial Treatment of DNA in the *Myriad Genetics* Litigation, 127
Ian Binnie and Vanessa Park-Thompson

Patentability of Genes: A European Union Perspective, 139
Paul Cole

Contents

Decoding Gene Patents in Australia, 151

Adam Denley and James Cherry

The Impact of *Myriad* and *Mayo*: Will Advancements in the Biological Sciences Be Spurred or Disincentivized? (Or Was Biotech Patenting Not Complicated Enough?), 163

Jennifer Gordon

The Impact of *Myriad* on the Future Development and Commercialization of DNA-Based Therapies and Diagnostics, 175

Michele Wales and Eddie Cartier

Research Use Exemptions to Patent Infringement for Drug Discovery and Development in the United States, 189

Alicia A. Russo and Jason Johnson

Research Exemption/Experimental Use in the European Union: Patents Do Not Block the Progress of Science, 199

Hans-Rainer Jaenichen and Johann Pitz

Patentability of Stem Cells in the United States, 209

Sarah E. Fendrick and Donald L. Zuhn, Jr.

Patenting Stem Cell Technologies in Europe, 215

Andrew Sheard

The Patentability of Stem Cells in Australia, 225

Jenny Petering and Prue Cowin

Patentability of Self-Replicating Technologies, 235

Richard H. Shear

Protecting Traditional Knowledge Related to Biological Resources: Is Scientific Research Going to Become More Bureaucratized?, 243

Prashant Reddy and Malathi Lakshmikumaran

Licensing Biotech Intellectual Property in University–Industry Partnerships, 253

Vladimir Drozdoff and Daryl Fairbairn

Trade Secrets in Life Science and Pharmaceutical Companies, 265

Tara Nealey, Ronald M. Daignault, and Yu Cai

Protecting Trade Secrets in Canada, 275

Noel Courage and Janice Calzavara

Index, 283

Preface

THE YEAR 1980 WAS TRANSFORMATIVE FOR BIOTECHNOLOGY. By a narrow decision of 5–4, the U.S. Supreme Court, in *Diamond v. Chakrabarty* (447 U.S. 303, 206 USPQ 193) (1980), found that Ananda Chakrabarty’s patent application covering oil-digesting bacteria constituted patentable subject matter under U.S. patent law and paved the way for the commercialization of biotechnology to become the highly dynamic industry it is today. Other countries, such as Australia, Canada, and the United Kingdom, soon followed suit and found microorganisms to be patentable subject matter. No one could have foreseen then the breakneck speed at which biotechnology would advance and the accompanying patents that would be granted. The Supreme Court’s statement in *Chakrabarty* that “anything under the sun made by man” is patentable subject matter gave the United States Patent and Trademark Office (USPTO) license to broaden the boundaries of patentable subject matter in the life sciences and grant patents in respect of a wide variety of biotechnological innovations. Entrepreneurial scientists and patent lawyers have, in turn, tested the limits of these boundaries and have occasionally been pushed back by the courts. Even though “anything under the sun made by man” may be patentable subject matter, recent cases challenging the patentability of genes and diagnostic methods, at least in the United States, clearly suggest that “anything under the sun made by man,” at least with respect to the patentability of biotechnological inventions, is not a settled point of law. In the United States, the *Association for Molecular Pathology v. Myriad Genetics, Inc.* (133 S.Ct. 2107) (2013) and *Mayo Collaborative Servs. v. Prometheus Labs., Inc.* (132 S. Ct. 1289) (2012) cases have rekindled the debate on the patentability of biotechnological inventions, primarily the patentability of genes and diagnostic methods.

In 2012, as the debate on the patentability of genes and diagnostics was heating up in the United States, we decided it would be beneficial to organize a conference on the patentability of this subject matter to be hosted by Cold Spring Harbor Laboratory in March 2013. The aim was to bring together individuals from around the world with various backgrounds to explore the scientific, legal, ethical, and social issues related to the patenting of genes and diagnostic methods. One question that was raised repeatedly was whether those addressing and deciding on such important issues were well enough versed with the underlying science to make the proper arguments and ultimately decide for or against the patentability of complex biotechnological inventions. We now know the vastly different outcomes on the eligibility of genes as patentable subject matter in the United States and Australia based on decisions handed down by the United States Supreme Court (USSC) and the Federal Court of Australia Full Court (FCAFC). Although patent law and the application of it is highly jurisdictional, a reading of both decisions clearly shows that the Justices on the FCAFC were heavily influenced in their decision to allow the patentability of genes, in Australia, by the underlying science (*D’Arcy v Myriad Genetics Inc.* [2014] FCAFC 115). In fact, portions of the FCAFC decision and the Justice’s reasoning read much like a molecular biology text. On the other hand, in the United States, where genomic DNA was held to be nonpatentable subject matter (although cDNA was found to be eligible), it is not difficult to see that the Justices on the USSC struggled with the science and relied instead on analogies and metaphors that had little or no bearing on the complex science used to isolate the *BRCA1* and *BRCA2* genes. Further, the USSC’s

Preface

decision has been exacerbated by the USPTO's proposed original guidelines¹ to its examining corps when determining subject matter eligibility of claims reciting or involving laws of nature, natural phenomena, and natural products as a result of the USSC's *Myriad* and *Mayo* decisions. The proposed highly controversial guidelines would have effectively prohibited obtaining patent protection for most products derived from nature. However, after much public feedback, the USPTO has now significantly scaled back these restrictions.² One of the tests that will be applied to the eligibility of inventions related to products of nature is whether the claimed subject matter is "markedly different" from what is found in nature. This test will undoubtedly be subjective and the question of how "markedly different" the claimed subject matter as a whole is from what is found in nature will remain uncertain until the courts provide more clarity in the future. Only time will tell what impact, if any, the USSC's decisions and the USPTO's guidelines, once adopted, will have on the biotechnology industry.

Canadian courts have often stated that a patent should be approached with a mind *willing* to understand³ (our emphasis). But, by the same token, we would argue that a patent should also be approached with a mind *able* to understand. We have attempted here to bring together a collection of views on patent law, by distinguished experts, as they apply to biotechnological inventions for scientists, graduate students, and technicians—individuals at the forefront of innovation in the life sciences. The chapters are also meant for technology transfer professionals and those involved in the commercialization of biotechnological innovations with little to no patent law background. The various chapters try to introduce to the reader basic principles of patent law as they may apply to the life sciences in various major jurisdictions. Our instruction to the authors was to remove as much legal jargon as possible and introduce the concepts with as many real examples as possible. We are grateful to all our contributors for the immense time and effort put into writing these chapters and simplifying complex legal concepts that are often taken for granted in their daily work.

We strongly feel that those at the front lines of biotechnological innovation should increasingly be exposed to concepts of patent law and should have a good working knowledge of how patent law works to protect their hard work that may eventually be commercialized. To that end, we are grateful to Richard Sever of Cold Spring Harbor Laboratory Press for initiating this project and allowing us to coedit this volume—an area not within the Press's comfort zone. Finally, we would like to thank Barbara Acosta, also of Cold Spring Harbor Laboratory Press. Barbara was assigned as project manager and kept the whip cracking to make sure we were on track and on time as much as possible.

A note of caution: This is not a text on patent law. No single book can attempt to explain the complexities of patent law and its varied application in various jurisdictions. Accordingly, these chapters do not, by any means, cover all aspects of patent law. We do not expect nor advise the reader begin to

¹*Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural Products* ("Revised Guidance"), which was attached to the Memorandum issued on March 4, 2014 by Andrew Hirshfeld, Deputy Commissioner for Patent Examination Policy entitled, *2014 Procedure For Subject Matter Eligibility Analysis of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products* ("Cover Memo").

²DEPARTMENT OF COMMERCE, *United States Patent and Trademark Office*, 37 CFR Part 1 [Docket No. PTO-P-2014-0058] 2014, *Interim Guidance on Patent Subject Matter Eligibility* issued December 15, 2014. This Interim Eligibility Guidance supplements the June 25, 2014, Preliminary Examination Instructions in view of the Supreme Court decision in *Alice Corp.* (June 2014 Preliminary Instructions) and supersedes the March 4, 2014, Procedure For Subject Matter Eligibility Analysis Of Claims Reciting Or Involving Laws Of Nature/Natural Principles, Natural Phenomena, And/Or Natural Products (March 2014 Procedure) issued in view of the Supreme Court decisions in *Myriad* and *Mayo*.

³*Whirlpool Corp. v. Camco Inc.* ((2000), 9 C.P.R. (4th), 129 (S.C.C.)) at paragraph 49; citing *Lister v. Norton Brothers and Co.* ((1886), 3 R.P.C. 199, (Ch.D.)) at page 203. The actual quote from *Lister* is that a patent "must be read by a mind willing to understand, not by a mind desirous of misunderstanding"; *Teva Canada Limited v. Novartis AG*, [2013 FC 141] at paragraphs 73 and 282.

attempt to draft his or her own patent application or analyze an issued patent for validity or invalidity based on the information in these chapters. The reader will be quick to realize that ultimately patent law is highly complex, jurisdictional, fact-specific, and unfortunately not an exact science. We hope, however, that after having read these chapters, the reader will have a better appreciation of how patent law works, especially as it applies to the life sciences, and be *willing* and *able* to have a meaningful discussion with their patent counsel when deciding to apply for patent protection.

SALIM MAMAJIWALLA
In(sci)te IP

ROCHELLE SEIDE
R. Seide Consulting, LLC

This is a free sample of content from Intellectual Property in Molecular Medicine.
[Click here](#) for more information on how to buy the book.

This is a free sample of content from Intellectual Property in Molecular Medicine.
[Click here](#) for more information on how to buy the book.

Intellectual Property in Molecular Medicine

A subject collection from *Cold Spring Harbor Perspectives in Medicine*

This is a free sample of content from Intellectual Property in Molecular Medicine.
[Click here](#) for more information on how to buy the book.